Former HUL MD & CEO Rohit Jawa to join Marico board as independent director. Jawa brings 37 years of Unilever experience, including leadership roles in India, China and Southeast Asia 1 hour ago November 3, 2026 MUMBAI: Former Hindustan Unilever (HUL) managing director and CEO Rohit Jawa is set to join Marico as an independent director, bringing nearly four decades of experience at Unilever to the consumer goods company's board. Jawa led HUL from April 2023 to July 2025, while also serving as president of Unilever South Asia and a member of the Unilever Leadership Executive. During his tenure, he steered the company through a muted post-pandemic consumption environment, with a focus on strengthening competitiveness, market share and its portfolio. Before taking charge of HUL, Jawa served as Unilever's global chief of transformation from April 2022 to March 2023, leading a restructuring that shifted the company from a geography-led to a category-led operating model. He was chairman of Unilever China and executive vice-president of North Asia between 2017 and 2022, overseeing a business that he says grew to around $3.5 billion in revenue. Earlier, he was chairman and CEO of Unilever Philippines, where he led the business through a period of growth and transformation. Jawa's other assignments included global vice-president of marketing operations, regional vice-president of laundry for Unilever Asia and leadership roles in Vietnam and India. He joined Hindustan Unilever as a management trainee in 1988. Since leaving HUL, Jawa has taken up advisory and operating roles with Warburg Pincus, Bain & Company and Bessemer Venture Partners, focusing on growth strategy, transformation, market development and value creation. He is a graduate of Harvard Business School's Advanced Management Programme.

Warburg pincus-backed Appasamy acquires German manufacturer RUCK could the deal strengthen global ophthalmic surgery? Published: 26 Oct 2026 The global medical device industry is increasingly focusing on strategic acquisitions to strengthen technological capabilities, expand international operations, and improve access to specialized healthcare solutions. As demand for advanced surgical equipment grows, medical technology companies are exploring partnerships that combine established manufacturing expertise with innovative product portfolios. On October 22, 2026, reports confirmed that Chennai-based Appasamay Associates, backed by global private equity firm Warburg Pincus, had acquired Germany-based RUCK GmbH, a manufacturer of ophthalmic surgical products and systems. The acquisition brings specialized phaco-vitrectomy technology into Appasamy's portfolio, strengthening its capabilitites in cataract and vitreoretinal surgery. The financial details of the transaction have not been disclosed. The development highlights the growing role of cross-border acquisitions in expanding India's medical technology industry and strengthening its position in international ophthalmology markets. Appasamy expands it's ophthalmic surgical technology portfolio. The acquisition of RICK represents a strategic step for Appasamy Associates as the company seeks to expand its presence in specialized ophthalmic surgery. RUCK brings more than 40 years of experience in developing surgical products and systems for eye care professionals. Headquartered in Eschweiler, Germany, RUCK manufactures the Qube Pro, Qube, and Pentasys surgical systems. These platforms are used in ophthalmic procedures, including cataract and vitreoretinal surgeries, and have an established presence in Germany and the Benelux region. By integrating RUCK's technologies, Appasamy can broaden its existing range of ophthalmic products beyond intraocular lenses, diagnostic equipment, and surgical instruments. The acquisition is expected to strengthen its ability to offer more comprehensive solutions to ophthalmologists and healthcare providers. According to Appasamy Chief Executive Officer Senthil Kumar, there is a clear need in India for a dependable, CE-marked phaco-vitrectomy platforms, alongside opportunities for such solutions in international markets. The company sees RUCK's Qube Pro system as an important addition to addressing these requirements. Understanding phaco-vitrectomy technology. Phaco-vitrectomy technology combines capabilities used in cataract surgery and vitreoretinal procedures. Cataract surgery involves removing the eye's clouded natural lens, while vitreoretinal surgery addresses conditions affecting the retina and vitreous, the gel-like substance inside the eye. These procedures require specialized equipment that supports surgical precision, reliable performance, and effective management of different stages of an operation. Access to advanced surgical systems is particularly important as healthcare providers increasingly adopt specialized procedures for complex eye conditions. RUCK's existing technology portfolio gives Appasamy an opportunity to strengthen its presence in this segment. Combining the German manufacturers' engineering expertise with Appasamy's established manufacturing and distribution capabilities could also support braoder access to specialized surgical equipment. However, the commercial impact will depend on product integration, regulatory requirements, market acceptance, and the company's ability to expand distribution across the target region. Appasamy's manufacturing strength and global reach. Founded in 1978 and headquartered in Chennai, Appasamy Associates has developed a substantial presence in the ophthalmic medical device industry. Its product portfolio includes intraocular lenses (IoLs), surgical systems, diagnostic equipment, lasers, and microsurgical instruments. The company manufactures approximately five million intraocular lenses annually and has supplied more than 100 million lenses worldwide. Its products are available in over 100 countries, reflecting an established international distribution network. Appasamy also operates through a network serving more than 20,00 ophthalmologist in India. This existing reach could provide a platform for introducing RUCK's specialized surgical systems to additional customers, subject to applicable regulatory approvals and commercial arrangements. The company's flagship hydrophobic intraocular lens brand, SupraPhob, has recorded, more than 15 million lenses sold. Its established product portfolio and manufacturing capabilities provide a foundation for expanding into complementary surgical technologies. The company has also established medical technology centers of excellence in Denmark and San Francisco, supporting its broader international development ambition Why the acquisition matters for India's ophthalmology market. India's ophthalmology sector presents opportunities for manufacturers developing affordable, reliable, and technologically advanced surgical equipment. Cataracts remain an important cause of vision impairment, while retinal disorders and other eye conditions create demand for specialized diagnostic and surgical services. Expanding access to suitable equipment can help healthcare providers manage a wider range of ophthalmic conditions. However, affordability, trained surgical personnel, infrastructure, maintenance services, and availability across different regions remain important considerations. RUCK's technology could help Appasamy address a specialized segment of the surgical market. Its existing networks of ophthalmologists may also provide an opportunity to introduce these systems to Indian healthcare institutions. The acquisition reflects a wider industry trend in which Indian medical technology companies are pursuing international partnerships and acquisitions to access established technologies, engineering capabilities, and overseas markets. For Appasamy, the transaction offers a potential route to expand its product portfolio while strengthening its presence in higher-value surgical equipment. Warburg Pincus supports Appasamy's expansion strategy. Warburg Pincus acquired a stake in Appasamy Associated in April 2024, marking a significant investment in India's ophthalmic medical device sector. The investment supported the company's next phase of development and created a platform for pursuing growth opportunities. The RUCK acquisition aligns with a strategy of expanding through complementary technologies and international operations. Rather than relying solely on organic product development, Appasamy can gain access to an established specialist manufacturer and its existing surgical systems. For RUCK, joining Appasamy provides an opportunity to reach additional markets and benefit from the resources and distribution capabilities of a larger ophthalmic business. Importantly, Appasamy plans to retain RUCK's engineering and product development operations in Germany. Maintaining these capabilities could help preserve technical expertise and support the continued development of the Qube Pro platform and future products. Future outlook for global ophthalmic medical devices. The acquisition could strengthen Appasamy's position in the global ophthalmology market by combining India manufacturing and distribution capabilities with German surgical technology expertise. Future opportunities may include expanding access to specialized surgical platforms, developing complementary products, and increasing the company's presence in international markets. The success of these opportunities will depend on effective integration, product development, regulatory compliance, and the ability to meet the needs of surgeons and healthcare institutions. The transaction also highlights how cross-border acquisition can support technology transfer and portfolio diversification in the medical device industry. As demand for specialized eye care continues, manufacturers with broader product offerings may be better positioned to serve different clinical requirements. Nevertheless, the acquisition's long-term impact cannot yet be determined because its financial terms and expected revenue contribution have not been disclosed. Conclusion. Appasamy Associates' acquisition of Germany-based RUCK GmbH represents a strategic development in the global ophthalmic medical device industry. By adding specialized phaco-vitrectomy technology and retaining RUCK's German engineering and product development operations, Appasamy aims to strengthen its surgical technology portfolio and expand its international reach. The deal builds on Appasamy's established manufacturing capabilities, global distribution network, and backing from Warburg Pincus. It could create new opportunities to introduce specialized surgical systems to Indian and international healthcare providers. Ultimately, the acquisition's success will depend on effective integration, product innovation, regulatory requirements, and commercial adoption. If these elements align, the transaction could support Appasamy's ambitions to become a more comprehensive provider of ophthalmic medical technology and contribute to the continued development of specialized eye care solutions.